





The 1st Asia Pacific Congress on
**CONTROVERSIES TO CONSENSUS IN DIABETES,
OBESITY AND HYPERTENSION**



Shanghai • China • June 2-5, 2011

**2nd ANNOUNCEMENT
AND CALL FOR ABSTRACTS**

www.codhy.com/AP
codhyAP@codhy.com





1st Asia Pacific Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy)
Shanghai • China • June 2-5, 2011

Dear Friends and Colleagues,

We are proud to announce that the 1st Asia Pacific Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy) will take place in Shanghai, China on June 2-5, 2011.

The success of the 1st and 2nd World CODHy Congresses, which took place in Europe, paved the way for the 1st locally oriented CODHy Congress, which was held in Buenos Aires, Argentina in 2010.

The 1st Latin America CODHy Congress was a vibrant academic event with a regional focus and attracted approximately 2000 participants from 52 countries.

Academically, the 1st Asia Pacific CODHy Congress will raise the most dynamic and controversial topics facing clinicians in the fields of Diabetes, Obesity and Hypertension in an exciting debate forum. The Congress will promote excellence in these fields by seeking to shed light on ongoing and challenging debates and to bridge gaps between the expansion of information and its consolidation in clinical practice.

Allowing ample time for speaker-audience discussion, the Congress aims at reaching up-to-date and agreed-upon answers to ongoing debates even when data remains limited, through evidence-based medicine and expert opinion. Participants will have the opportunity to take part in this vibrant meeting which will facilitate discussions on the shared experiences and opinions of leading local and international experts.

The 1st Asia Pacific CODHy Congress will emphasise issues related to the region in terms of epidemiology, genetics, diagnostics, typical complications and distinctive responses to treatments.

Many of the Faculty members will be local in order to facilitate the involvement of a large number of participants in the debates and to discuss typical regional problems.

We invite you to participate in the 1st Asia Pacific CODHy Congress in Shanghai.

Sincerely,

Prof. **Markolf Hanefeld** • Prof. **Linong Ji** • Prof. **Guang Ning** • Prof. **Itamar Raz** • Prof. **Shaukat M. Sadikot**
Co-Chairpersons

CO-CHAIRPERSONS

Markolf Hanefeld
Germany

Linong Ji
China

Guang Ning
China

Itamar Raz
Israel

Shaukat M. Sadikot
India

ORGANIZING COMMITTEE

A. Ceriello, UK

J. Chan, China (HK)

J. Davidson, USA

R.A. DeFronzo, USA

S. Del Prato, Italy

V.A. Fonseca, USA

V. Hainer, Czech Republic

P. Home, UK

N. Hotta, Japan

W. Lee, Singapore

P.M. Nilsson, Sweden

A. Ramachandran, India





SCIENTIFIC COMMITTEE

- | | | |
|--|-----------------------------------|---|
| M. Al-Arouj , Kuwait | M. Laakso , Finland | F. Rubino , USA |
| R. Bitzur , Israel | N.M. Lalic , Serbia | L.M. Ruilope , Spain |
| E. Bonora , Italy | H. Lebowitz , USA | W. Scherbaum , Germany |
| C. Cockram , China (HK) | L.A. Leiter , Canada | G. Schernthaner , Austria |
| J.H. de Vries , The Netherlands | S. Madsbad , Denmark | S. Soegondo , Indonesia |
| D. de Zeeuw , The Netherlands | D.M. Mannino , USA | E. Standl , Germany |
| M. Donath , Switzerland | J. Meigs , USA | P. Tønnesen , Denmark |
| R. Fagard , Belgium | L. Meneghini , USA | D. Tschöpe , Germany |
| B. Frier , UK | D. Micic , Serbia | C. Tsigos , Greece |
| B. Gallwitz , Germany | A. Natali , Italy | J. Tuomilehto , Finland |
| E. Grossman , Israel | M.A. Nauck , Germany | T. Vilsbøll , Denmark |
| S. Heller , UK | A.K. Nikousokhan , Iran | R. Weiss , Israel |
| B. Hirshberg , Israel | W. Nitayanant , Thailand | B. Wolffenbuttel , The Netherlands |
| P. Iozzo , Italy | U. Pagotto , Italy | J.T. Woo , Korea |
| A. Kadir , Malaysia | D. Pei , Taiwan | K.H. Yoon , Korea |
| A. Keidar , Israel | P. Pozzilli , Italy | A. Zanchetti , Italy |
| L. Keuky , Cambodia | M.T. Que , The Philippines | D. Ziegler , Germany |
| A. Khan , Bangladesh | P. Raskin , USA | |

FACULTY

(preliminary list)

- | | | |
|--------------------------------------|--------------------------------|----------------------------------|
| K. Abdul Kadir , Malaysia | P. Home , UK | P. Raskin , USA |
| J. Chan , China (HK) | D. Hu , China | I. Raz , Israel |
| Y.S. Cho , Korea | C.K. Huang , Taiwan | F. Saad , Germany |
| L.M. Chuang , Taiwan | E. Imai , Japan | S.M. Sadikot , India |
| J. Davidson , USA | B. Itzhak , Israel | G. Schernthaner , Austria |
| R.A. DeFronzo , USA | L. Ji , China | W.H-H. Sheu , Taiwan |
| D. de Zeeuw , The Netherlands | K. Kario , Japan | S. Soegondo , Indonesia |
| S. Del Prato , Italy | L. Keuky , Cambodia | E. Standl , Germany |
| D. Dicker , Israel | G. Kimura , Japan | P. Tong , China (HK) |
| X.H. Ding , China | A. Kumar , India | L. Van Gaal , Belgium |
| R. Eldor , Israel | W. Lee , Singapore | H. Wang , China |
| A. El-Sayed , Egypt | Y.S. Lee , Singapore | J. Wang , China |
| V.A. Fonseca , USA | L. Liu , China | R. Weiss , Israel |
| S. Goto , Japan | X. Liu , Australia | S.K.H. Wong , China (HK) |
| E. Grossman , Israel | R. Ma , China (HK) | W.Y. Yang , China (HK) |
| V. Hainer , Czech Republic | P.M. Nilsson , Sweden | X. Yang , China |
| M. Hanefeld , Germany | G. Ning , China | K.H. Yoon , Korea |
| S. Heller , UK | J. Palmer , USA | Z. Yuqing , China |
| B. Hirshberg , USA | P. Pozzilli , Italy | J. Zhao , USA |
| | A. Ramachandran , India | |



PRELIMINARY SCIENTIFIC PROGRAM

Friday, June 3, 2011

HALL A

08:30-10:00 **PLENARY SESSION 1 FUTURE THERAPY**

- Opening Remarks
- Inflammation and anti inflammatory drugs to treat diabetes- **V.A. Fonseca**, USA
- Genetics of type 2 diabetes in the Chinese population - TBA
- Recent trial to prevent CV disease: Is this the answer or has it created more questions? - **J. Chan**, China (HK)
- The role of Beta cell insulin resistance: Worldwide vs. China - **R. DeFronzo**, USA

10:00-10:30 *Coffee Break*

10:30-12:00 **SESSION 2 DIABETES THERAPY - FOCUS ON ASIA**

- First line therapy:
Glucosidase INH and Sulfonylurea - **M. Hanefeld**, Germany
Metformin - **S. Del Prato**, Italy
- Second line therapy:
GLP1/ DPP4 INH vs. Secretagogue/ Insulin
GLP1/ DPP4 INH - **A. Kumar**, India
Secretagogue/ Insulin - **R. Eldor**, Israel

12:00-12:10 *Technical Break*

12:10-13:00 **SESSION 3 STUDIES OF HYPERTENSION CONTROL IN ASIA**

- CHIEF trial - TBA
- FEVER study - **Z. Yuqing**, China

13:00-14:00 *Lunch Break*

14:00-15:30 **SESSION 4 INSULIN THERAPY IN T2D - ASIA VS. THE ROW**

- Initiation of Insulin:
Not too early - TBA
Not too late - **A. Kumar**, India
- Oral hypoglycaemic with long-acting analogs - **S. Soegondo**, Indonesia
- Place of TZD in Asian diabetic patients - **P. Home**, UK

15:30-16:00 *Coffee Break*

16:00-17:30 **SESSION 5 THERAPEUTIC APPROACH TO YOUTH WITH T2DM? IS IT EFFICIENT FOR ASIANS?**

- Insulin, metformin TZD, glucosidase INH - **W. Lee**, Singapore
- Cure for T2D: Dreams and reality - **I. Raz**, Israel
- Type 1 Diabetes in Asia - Differences and similarities to the ROW - **J. Palmer**, USA
- LADA in Asia - **P. Pozzilli**, Italy

HALL B

10:30-12:00 **SESSION 6 HYPERTENSION CONTROVERSIES**

- The risk of hypertension in diabetic patients - **D. Dicker**, Israel
- Should we change the target blood pressure in diabetic patients?
Yes - **E. Grossman**, Israel
No - **D. Hu**, China
- Should we avoid antihypertensive drugs that increase glucose levels?
Yes - **E. Standl**, Germany
No - TBA

12:00-12:10 *Technical Break*

12:10-13:00 **SESSION 7 MEET THE PROFESSOR**

- Diabetes and Alzheimer - **K. Abdul Kadir**, Malaysia
- Oral Presentation: Oral insulin - **R. Eldor**, Israel

13:00-14:00 *Lunch Break*

14:00-15:30 **SESSION 8 NOVEL DRUGS FOR T2D IN ASIAN POPULATION**

- Efficacy - **J. Davidson**, USA
- Safety and hypoglycaemia and mortality - **S. Heller**, UK
- The role of iron in diabetes and its complications- was iron deficiency protective in Asia and have we lost the protection? - **V.A. Fonseca**, USA

15:30-16:00 *Coffee Break*

16:30-17:30 **SESSION 9 RENAL AWARENESS**

- 2010-2011 Randomize control studies to protect the kidney
- PLANET & VITAL - **D. de Zeeuw**, The Netherlands
 - SHARP - **J. Chan**, China (HK)
 - Does sodium intake help in your patients' treatment? - **G. Kimura**, Japan

HALL C

10:30-12:00 **SESSION 10 CARDIOMETABOLIC RISK ASSESSMENT AND METABOLIC SYNDROME CONTROVERSIES**

- Drug therapy for Pre Diabetes
Yes - **K.H. Yoon**, Korea
No - **S.M. Sadikot**, India

12:00-12:10 *Technical Break*

12:10-13:00 **SESSION 11 MEET THE PROFESSOR: HYPERTENSION E. Grossman, Israel**

- Resistant hypertension: Evaluation and treatment:
 - Definition and Diagnosis
 - How far should we go with the evaluation?
 - How to achieve blood pressure goal in diabetic patients
- Oral Presentation - TBA

13:00-14:00 *Lunch Break*



PRELIMINARY SCIENTIFIC PROGRAM

Friday, June 3, 2011

HALL C

14:00-15:30 **SESSION 12** **OPTIMISING DIABETES THERAPY**

- The status of diabetes control in Asia - **L.M. Chuang**, Taiwan
- Benefit of self-monitoring glucose control
Pro - **R. Ma**, China (HK)
Con - TBA
- Continuous glucose monitoring (CGM): For whom will it be beneficial? - **K.H. Yoon**, Korea

15:30-16:00 *Coffee Break*

16:30-17:30 **SESSION 13** **CARDIOVASCULAR RISK IN DIABETES FOCUSING ON ASIA**

- Improving CV risk and diabetes burden -
P. Tong, China (HK)
- Hypoglycaemia barrier to glucose control -
W.H-H. Sheu, Taiwan
- The role of diet in the development of hypglycaemia -
S. Heller, UK

Saturday, June 4, 2011

HALL A

08:30-10:00 **SESSION 14** **APPROACH TO PREVENTION OF DIABETES**

- Score for high risk in Diabetes in Asia - **G. Ning**, China
- High prevalence in the Gulf region - **A. El-Sayed**, Egypt
- Difference in candidate gene for T2D in Asia -
Y.S. Cho, Korea

10:00-10:30 *Coffee Break*

10:30-12:00 **SESSION 15** **WHAT IS OF SPECIAL IMPORTANCE FOR HYPERTENSION AND ITS TREATMENT IN ASIA?**

- The epidemiological perspectives for populations in transition - **L. Liu**, China
- Stroke more important than CHD in Asian countries - still true? - **K. Kario**, Japan
- A review of interventions studies including Asian patients with hypertension - **D. Hu**, China
- Which antihypertensive drugs to prefer in Asian patients? - **J. Wang**, China

12:00-12:10 *Technical Break*

12:10-13:00 **SESSION 16** **MEET THE PROFESSOR**

- Beta cell function and diabetes in China -
W.Y. Yang, China
- Oral Presentations - TBA

13:00-14:00 *Lunch Break*

14:00-15:30 **SESSION 17** **FDA CARDIOVASCULAR ASSESSMENT REQUIREMENTS: IMPLICATIONS FOR CLINICAL RESEARCH IN SOUTHEAST ASIA**

- Impact of the US FDA cardiovascular assessment requirements on the development of novel antidiabetes drugs - **B. Hirshberg**, Israel
- Global CV outcome studies, view point of the Chinese regulatory authority - TBA
- Application of global CV outcome studies for the Indian population and Indian regulatory authority - TBA

15:30-16:00 *Coffee Break*

16:00-17:30 **SESSION 18** **INDIVIDUALISED THERAPY IN ASIAN T2D PATIENTS**

- Are all Asian patients the same when it comes to diabetes? Case reports:
China/Japan - TBA
India - **A. Kumar**, India
Cambodia - **L. Keuky**, Cambodia
- Gene polymorphism and T2D - TBA

HALL B

08:30-10:00 **SESSION 19** **EXTRA GLYCAEMIC EFFECTS OF INCRETIN BASED THERAPY IN T2D**

- The heart - **S. Del Prato**, Italy
- The brain - **P. Raskin**, USA
- The vascular system - TBA
- The kidney - TBA

10:00-10:30 *Coffee Break*



PRELIMINARY SCIENTIFIC PROGRAM

Saturday, June 4, 2011

HALL B

10:30-12:00 **SESSION 20** **TREATMENT GOALS IN DIABETES**

- A1C for diagnosis and monitoring in Asia (How accurate is A1C in Asia?) - TBA
- Individualized A1C targets - **L. Ji**, China
- Should we aim to normalize A1C?
Pro - **E. Standl**, Germany
Con - **K. Abdul Kadir**, Malaysia

12:00-12:10 *Technical Break*

12:10-13:00 **SESSION 21** **ORAL PRESENTATIONS** TBA

13:00-14:00 *Lunch Break*

14:00-15:30 **SESSION 22** **EVIDENCE FROM CLINICAL TRIALS IN DIABETES**

- Specific OHG effects on CVD - TBA
- HDL: unmet challenge - **L. Van Gaal**, Belgium
- Statin or combination - **I. Raz**, Israel

15:30-16:00 *Coffee Break*

16:00-17:30 **SESSION 23** **NEW TRENDS IN TYPE 1 DIABETES**

- The increased incidence of type 1 diabetes worldwide: what to blame? - **P. Pozzilli**, Italy
- Promising treatment to limit beta cell destruction - **J. Palmer**, USA
- Application of technology to the disease management - **R. Weiss**, Israel

HALL C

08:30-10:00 **SESSION 24** **HYPERTENSION**

- The "Pearls and Perils" of managing hypertension in people with diabetes
Pearls - **J. Wang**, China
Perils - **D. Hu**, China
- ACEs or ARBs as first line treatment of hypertension in diabetes - **E. Imai**, Japan
- Are all RASS blockers equal? - **P.M. Nilsson**, Sweden
- Association of angiotensin converting enzyme gene I/D polymorphism with type 2 diabetes mellitus - TBA

10:00-10:30 *Coffee Break*

10:30-12:00 **SESSION 25** **OBESITY IN ASIA: IS IT DIFFERENT FROM THE REST OF THE WORLD?**

- Rising burden of obesity in Asia - **A. Ramachandran**, India
- Do we need anti - obesity drugs?
Yes - **V. Hainer**, Czech Republic
No: Lifestyle intervention only - **L. Van Gaal**, Belgium

12:00-12:10 *Technical Break*

12:10-13:00 **SESSION 26** **MEET THE PROFESSOR**

- SGLT2 in Type 2 Diabetes - **G. Schernthaner**, Austria
- Oral Presentation - TBA

13:00-14:00 *Lunch Break*

14:00-15:30 **SESSION 27** **CV RISK AND INSULIN RESISTANCE IN CHILDHOOD - ASIAN PERSPECTIVE**

- Melancortin 3 receptor and Melancortin 4 receptor genetic mutations: The Asian perspective - **Y.S. Lee**, Singapore
- Metabolic syndrome - Early life exposure - **W. Lee**, Singapore
- Obesity and metabolic syndrome in Chinese children - **H. Wang**, China
- Bariatric surgery for obese adolescents with related comorbidity - **R. Weiss**, Israel

15:30-16:00 *Coffee Break*

16:00-17:30 **SESSION 28** **BIARIATRIC SURGERY IN OBESITY AND DIABETES - ASIA**

- Last resort in obese patients
Pro - **C.K. Huang**, Taiwan
Con - TBA
- Early in the obese patient with risk factors
Pro - **S.K.H. Wong**, China (HK)
Con - **W.H-H. Sheu**, Taiwan



1st Asia Pacific Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy)
Shanghai • China • June 2-5, 2011

PRELIMINARY SCIENTIFIC PROGRAM

Sunday, June 5, 2011

HALL A


08:30-10:00 **SESSION 29** **THE METABOLIC SYNDROME**

- Metabolic Syndrome - from a bunch of interrelated diseases to a cluster of premorbid risk factors - Is this the right way? - **M. Hanefeld**, Germany
- Can mind-body movement therapy combat central obesity and other indicators of metabolic syndrome-promising findings from recent trials - **X. Liu**, Australia
- Can testosterone effectively reduce the cardiovascular risk in men? - **F. Saad**, Germany
- Aspirin or other antiplatelet for primary prevention - **S. Goto**, Japan

10:00-10:30 *Coffee Break*

10:30-12:00 **PLENARY SESSION 30**

- Prevention of T2DM: Call for early intervention - **R.A. DeFronzo**, USA
- Diabetes and Cancer - **X. Yang**, China (HK)
- Insulin and Cancer - **P. Home**, UK
- Combination of GLP-1 analog and long acting insulin as third line therapy for type 2 diabetes - **G. Scherthaner**, Austria
- Closing Remarks



ABSTRACT SUBMISSION DEADLINE:
MARCH 22, 2011



1st Asia Pacific Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy)
Shanghai • China • June 2-5, 2011

GENERAL INFORMATION

DATES

June 2-5, 2011

LOCATION

Shanghai, China

VENUE

Kerry Hotel Pudong, Shanghai
No.1388 Hua Mu Road
Pudong, Shanghai, 201204
China

REGISTRATION FEES

	Early Registration until March 10, 2011	Late Registration from March 11 until May 24, 2011	From May 25, 2011 and On Site
Participants - Physicians and Scientists	€490	€550	€600
Residents*	€330	€380	€420
Nurses and Students	€150	€190	€220
Accompanying Persons		€140	

*Refers to non-tenured junior scientists. Registration form must be accompanied by documentation of residency or a letter from the head of department confirming their status. The letter should be on the department letterhead and addressed to the Registration Department of the Congress.

Note: Credit card payments (only) will be charged to your account in US\$ according to the rate of exchange to the Euro on the date of payment.

Registration fees include: Participation in scientific sessions, Congress bag, program and abstract book, all printed material of the Congress, invitation to the Welcome Reception, coffee breaks, lunch on Friday and Saturday

CONGRESS ORGANIZERS

Please do not hesitate to contact the Organizers for any additional information or assistance:
codhyAP@codhy.com

LIABILITY AND INSURANCE

The Congress Organizer will not accept liability for personal accidents, nor loss of, or damage to private property of participants, either during or directly arising from the 1st Asia Pacific Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy). Participants should make their own arrangements with respect to health and travel insurance at:

SPONSORS*



*Preliminary list



comtecMED
MEDICAL CONGRESSES

codhyAP@codhy.com
www.codhy.com/AP

Headquarters and Administration:
53 Rothschild Boulevard, PO Box 68
Tel Aviv 61000, Israel
Tel: +972-3-5666166
Fax: +972-3-5666177
Email: info@comtecmed.com

Comtec Spain:
Bailén, 95-97, pral. 1. a - 08009
Barcelona, Spain
Tel: +34-93-2081145
Fax: +34-93-4579291
Email: spain@comtecmed.com

Comtec China:
175 Xiang Yang Road South
Shanghai 200031, China
Tel: +86-21-54660460
Fax: +86-21-54660450
Email: china@comtecmed.com